Simulating Strategies for Improving Control of Hypertension Among Patients with Usual Source of Care in the United States: The Blood Pressure Control Model

Journal of General Internal Medicine

Volumn 30, Issue 8, 2015, Pages 1147-1155

  Fontil, Valy ^a,d   Bibbins Domingo, Kirsten ^a,b,d   Kazi, Dhruv S ^b,d   Sidney, Stephen ^a   Coxson, Pamela G ^a,d   Khanna, Raman ^a   Victor, Ronald G ^c   Pletcher, Mark J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

blood pressure control; hypertension; medication adherence; microsimulation modeling; treatment intensification; visit frequency

Indexed keywords

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; COHORT ANALYSIS; CONCEPTUAL FRAMEWORK; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PHYSICIAN; PRESCRIPTION; SIMULATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNITED STATES; AMBULATORY CARE; BIOLOGICAL MODEL; BLOOD PRESSURE; CLINICAL PRACTICE; COMPUTER SIMULATION; DRUG EFFECTS; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; MARKOV CHAIN; MONTE CARLO METHOD; ORGANIZATION AND MANAGEMENT; UTILIZATION;

ANTIHYPERTENSIVE AGENT;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COMPUTER SIMULATION; DELIVERY OF HEALTH CARE; DRUG PRESCRIPTIONS; HUMANS; HYPERTENSION; MARKOV CHAINS; MEDICATION ADHERENCE; MODELS, CARDIOVASCULAR; MONTE CARLO METHOD; OFFICE VISITS; PRACTICE PATTERNS, PHYSICIANS'; QUALITY OF HEALTH CARE; UNITED STATES;

EID: 84938208084     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-015-3231-8     Document Type: Article

References (51)

1. Yang Q, Cogswell ME, Flanders WD, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA. 2012;307(12):1273–83.
2. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757–64.
3. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.
4. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255–3264.
5. Landon BE, Hicks LS, O’Malley AJ, et al. Improving the management of chronic disease at community health centers. N Engl J Med. 2007;356(9):921–34.
6. Fung V, Huang J, Brand R, Newhouse JP, Hsu J. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther. 2007;29(5):972–84.
7. LaFleur J, Nelson RE, Sauer BC, Nebeker JR. Overestimation of the effects of adherence on outcomes: a case study in healthy user bias and hypertension. Heart. 2011;97(22):1862–9.
8. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010;303(20):2043–50.
9. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.
10. Navar-Boggan AM, Pencina MJ, Williams K, Sniderman AD, Peterson ED. Proportion of US adults potentially affected by the 2014 hypertension guideline. JAMA. 2014;311(14):1424–9.
11. Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2010;3:CD005182.
12. Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310(7):699–705.
13. Fletcher RD, Amdur RL, Kolodner R, et al. Blood pressure control among US veterans: a large multiyear analysis of blood pressure data from the Veterans Administration health data repository. Circulation. 2012;125(20):2462–8.
14. Abraham JM. Using microsimulation models to inform U.S. health policy making. Health Serv Res. 2013;48(2 Pt 2):686–95.
15. Turchin A, Goldberg SI, Shubina M, Einbinder JS, Conlin PR. Encounter frequency and blood pressure in hypertensive patients with diabetes mellitus. Hypertension. 2010;56(1):68–74.
16. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis. Circulation. 2012;126(5):569–78.
17. Khanna RR, Victor RG, Bibbins-Domingo K, Shapiro MF, Pletcher MJ. Missed opportunities for treatment of uncontrolled hypertension at physician office visits in the United States, 2005 through 2009. Arch Intern Med. 2012;172(17):1344–5.
18. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
19. Hill MN, Miller NH, DeGeest S. American Society of Hypertension Writing G. ASH position paper: Adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens (Greenwich). 2010;12(10):757–64.
20. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–7.
21. Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997.
22. Julius S, Kjeldsen SE, Brunner H, et al. VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens. 2003;16(7):544–8.
23. Glied S, Tilipman N. Simulation modeling of health care policy. Annu Rev Public Health. 2010;31:439–55.
24. Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health. 2001;4(5):348–61.
25. Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10):738–47.
26. Kristensen AH, Flottemesch TJ, Maciosek MV, et al. Reducing Childhood Obesity through U.S. Federal Policy: A Microsimulation Analysis. Am J Prev Med. 2014.
27. Farley TA, Dalal MA, Mostashari F, Frieden TR. Deaths preventable in the U.S. by improvements in use of clinical preventive services. Am J Prev Med. 2010;38(6):600–9.
28. Turner MJ, van Schalkwyk JM. Blood pressure variability causes spurious identification of hypertension in clinical studies: a computer simulation study. Am J Hypertens. 2008;21(1):85–91.
29. Daugherty SL, Powers JD, Magid DJ, et al. The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension. Hypertension. 2012;60(2):303–9.
30. Rose AJ, Berlowitz DR, Manze M, Orner MB, Kressin NR. Intensifying therapy for hypertension despite suboptimal adherence. Hypertension. 2009;54(3):524–9.
31. Holder KK. Interventions to improve blood pressure control in patients with hypertension. Am Fam Physician. 2007;76(3):373–4.
32. Fahey T, Schroeder K, Ebrahim S. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2006;2:CD005182.
33. Frieden TR, King SM, Wright JS. Protocol-based treatment of hypertension: a critical step on the pathway to progress. JAMA. 2014;311(1):21–2.
34. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47(3):345–51.
35. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339(27):1957–63.
36. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825–34.
37. Fontil V, Pletcher M, Khanna R, Guzman D, Victor R, Bibbins-Domingo K. Physician Underutilization of Effective Medications for Resistant Hypertension at Office Visits in the United States: NAMCS 2006–2010. Journal of General Internal Medicine. 2013:1–9.
38. Davis BR, Ford CE, Remington RD, Stamler R, Hawkins CM. The Hypertension Detection and Follow-up Program design, methods, and baseline characteristics and blood pressure response of the study population. Prog Cardiovasc Dis. 1986;29(3 Suppl 1):11–28.
39. Selby JV, Uratsu CS, Fireman B, et al. Treatment intensification and risk factor control: toward more clinically relevant quality measures. Med Care. 2009;47(4):395–402.
40. Stewart S, Carrington MJ, Swemmer CH, et al. Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ. 2012;345:e7156.
41. Magid DJ, Ho PM, Olson KL, et al. A multimodal blood pressure control intervention in 3 healthcare systems. Am J Manag Care. 2011;17(4):e96–103.
42. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.
43. Guthmann R, Davis N, Brown M, Elizondo J. Visit frequency and hypertension. J Clin Hypertens (Greenwich). 2005;7(6):327–32.
44. Clark CE, Smith LF, Taylor RS, Campbell JL. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. BMJ. 2010;341:c3995.
45. Morgado MP, Morgado SR, Mendes LC, Pereira LJ, Castelo-Branco M. Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy: Review and meta-analysis. Am J Health Syst Pharm. 2011;68(3):241–53.
46. Rader F, Elashoff RM, Niknezhad S, Victor RG. Differential treatment of hypertension by primary care providers and hypertension specialists in a barber-based intervention trial to control hypertension in Black men. Am J Cardiol. 2013;112(9):1421–6.
47. Vigen R, Shetterly S, Magid DJ, et al. A comparison between antihypertensive medication adherence and treatment intensification as potential clinical performance measures. Circ Cardiovasc Qual Outcomes. 2012;5(3):276–82.
48. Manze M, Rose AJ, Orner MB, Berlowitz DR, Kressin NR. Understanding racial disparities in treatment intensification for hypertension management. J Gen Intern Med. 2010;25(8):819–25.
49. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103(9):1245–9.
50. Patel NC, Crismon ML, Miller AL, Johnsrud MT. Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy. Pharmacotherapy. 2005;25(9):1242–7.
51. Hypertension EETFftMoA. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31(10):1925–38.